115 related articles for article (PubMed ID: 22201761)
21. [Establishment of Cytarabine-resistant Acute Lymphoblastic Leukemia Cell Lines and Its Resistance Mechanism].
Qin X; Liu J; Chen X; Zhong FF; Yang Y; Zeng Y; Li C; Liu WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1403-1410. PubMed ID: 34627417
[TBL] [Abstract][Full Text] [Related]
22. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
23. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C
Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Galmarini CM; Clarke ML; Santos CL; Jordheim L; Perigaud C; Gosselin G; Cros E; Mackey JR; Dumontet C
Int J Cancer; 2003 Oct; 107(1):149-54. PubMed ID: 12925971
[TBL] [Abstract][Full Text] [Related]
25. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
26. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
[TBL] [Abstract][Full Text] [Related]
27. All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.
Freund A; Rössig C; Lanvers C; Gescher A; Hohenlöchter B; Jürgens H; Boos J
Ann Oncol; 1999 Mar; 10(3):335-8. PubMed ID: 10355579
[TBL] [Abstract][Full Text] [Related]
28. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
[TBL] [Abstract][Full Text] [Related]
29. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
30. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
Horber DH; Schott H; Schwendener RA
Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
32. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
33. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
[TBL] [Abstract][Full Text] [Related]
34. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
35. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
[TBL] [Abstract][Full Text] [Related]
36. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
Adema AD; Losekoot N; Smid K; Kathmann I; Myhren F; Sandvold ML; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):394-9. PubMed ID: 20544525
[TBL] [Abstract][Full Text] [Related]
37. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
[TBL] [Abstract][Full Text] [Related]
39. Human immunodeficiency virus type 1 induces 1-beta-D-arabinofuranosylcytosine resistance in human H9 cell line.
Yusa K; Oh-hara T; Tsukahara S; Tsuruo T
J Biol Chem; 1992 Aug; 267(24):16848-50. PubMed ID: 1512227
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]